Harnessing synthetic biology to develop novel psychedelic therapies

PsyBio Therapeutics is poised to fully develop a cost competitive solution for human clinical testing of these tryptamine therapeutic candidates as new chemical entities possessing key advantages over current in-clinic treatments for a range of mental health conditions impacting roughly 1 billion people globally.KEY FACTS: Globally, individuals with untreated mental health conditions have a median life expectancy that is approximately 10 years shorter than mentally healthy individuals. Recombinant psilocybin biosynthesis was first reported in 2018 in Aspergillus nidulans, followed by the first bacterial biosynthesis in Escherichia coli in 2019 and a 2020 study in Saccharomyces cerevisiae.Acknowledgments Figure is created with BioRender.com.Declaration of interests J.A.J. is the chairman of the scientific advisory board and a significant stakeholder at PsyBio Therapeutics.